U

United Laboratories International Holdings Ltd
HKEX:3933

Watchlist Manager
United Laboratories International Holdings Ltd
HKEX:3933
Watchlist
Price: 12.3 HKD 4.77%
Market Cap: 22.3B HKD
Have any thoughts about
United Laboratories International Holdings Ltd?
Write Note

United Laboratories International Holdings Ltd
EPS (Diluted)

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

United Laboratories International Holdings Ltd
EPS (Diluted) Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company EPS (Diluted) CAGR 3Y CAGR 5Y CAGR 10Y
U
United Laboratories International Holdings Ltd
HKEX:3933
EPS (Diluted)
ÂĄ1
CAGR 3-Years
38%
CAGR 5-Years
24%
CAGR 10-Years
16%
G
Grand Pharmaceutical Group Ltd
HKEX:512
EPS (Diluted)
HK$0
CAGR 3-Years
3%
CAGR 5-Years
17%
CAGR 10-Years
28%
Sino Biopharmaceutical Ltd
HKEX:1177
EPS (Diluted)
ÂĄ0
CAGR 3-Years
-25%
CAGR 5-Years
-14%
CAGR 10-Years
11%
C
China Traditional Chinese Medicine Holdings Co Ltd
HKEX:570
EPS (Diluted)
ÂĄ0
CAGR 3-Years
-21%
CAGR 5-Years
-10%
CAGR 10-Years
3%
C
China Resources Pharmaceutical Group Ltd
HKEX:3320
EPS (Diluted)
HK$1
CAGR 3-Years
27%
CAGR 5-Years
6%
CAGR 10-Years
N/A
H
HUTCHMED (China) Ltd
HKEX:13
EPS (Diluted)
$0
CAGR 3-Years
42%
CAGR 5-Years
17%
CAGR 10-Years
N/A
No Stocks Found

United Laboratories International Holdings Ltd
Glance View

Market Cap
22.3B HKD
Industry
Pharmaceuticals

United Laboratories International Holdings Ltd. has carved a significant niche in the global pharmaceutical industry, primarily through its prowess in producing antibiotic finished products and intermediates. Headquartered in Hong Kong, the company operates a diversified business model that spans manufacturing, marketing, and distribution of a wide range of pharmaceutical products. United Laboratories has established robust production facilities in China, positioning itself as one of the leading producers of antibiotics like amoxicillin and ampicillin. These products are vital to combating infections and are critical components in healthcare systems worldwide. The company's vertically integrated operations, coupled with its strategic focus on research and development, enable it to maintain cost efficiency while innovating continuously within its drug portfolio. The company's revenue mechanism is firmly rooted in its extensive distribution network and expansive market reach, which traverse not only the domestic markets but also international territories in North America, Europe, and Asia. United Laboratories leverages its strong brand presence and economies of scale to offer competitive pricing, enhancing its market penetration. Furthermore, it capitalizes on favorable regulatory frameworks in emerging markets, creating a tapestry of growth opportunities. The company's business strategy is also marked by its commitment to quality and adherence to stringent production standards, essential for maintaining trust and reliability among healthcare providers. Through these strategic channels, United Laboratories International Holdings Ltd. sustains its growth and profitability in the dynamic pharmaceutical landscape.

Intrinsic Value
21.1 HKD
Undervaluation 42%
Intrinsic Value
Price
U

See Also

What is United Laboratories International Holdings Ltd's EPS (Diluted)?
EPS (Diluted)
1.6 CNY

Based on the financial report for Jun 30, 2024, United Laboratories International Holdings Ltd's EPS (Diluted) amounts to 1.6 CNY.

What is United Laboratories International Holdings Ltd's EPS (Diluted) growth rate?
EPS (Diluted) CAGR 10Y
16%

Over the last year, the EPS (Diluted) growth was 30%. The average annual EPS (Diluted) growth rates for United Laboratories International Holdings Ltd have been 38% over the past three years , 24% over the past five years , and 16% over the past ten years .

Back to Top